Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Otorhinolaryngology

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 84 articles:
HTML format



Single Articles


    November 2022
  1. CHEN WY, Lu SH, Wang YM, Wang CW, et al
    Post-irradiation Sarcoma after Definitive Radiation Therapy for Nasopharyngeal Carcinoma.
    Radiother Oncol. 2022 Nov 23:S0167-8140(22)04560.
    PubMed     Abstract available


  2. LIU ZC, Zeng KH, Gu ZB, Chen RP, et al
    Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching.
    Radiother Oncol. 2022 Nov 18:S0167-8140(22)04554.
    PubMed     Abstract available


  3. WANG G, Huang C, Yang K, Guo R, et al
    Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04548.
    PubMed     Abstract available


  4. YAO JJ, Jin YN, Lin YJ, Zhang WJ, et al
    The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04547.
    PubMed     Abstract available


  5. BIN Y, Meng Z, Huang LL, Hu XY, et al
    Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04549.
    PubMed     Abstract available


  6. TAKADA A, Ichikawa Y, Nakamura S, Toyomasu Y, et al
    Preliminary results of reduced myocardial blood flow in the subacute phase after radiation therapy for thoracic esophageal cancer: A quantitative analysis with stress dynamic myocardial computed tomography perfusion imaging.
    Radiother Oncol. 2022 Nov 10. pii: S0167-8140(22)04546.
    PubMed    


  7. ZHONG Z, Wang D, Liu Y, Shao S, et al
    Lymph Drainage and Cervical Fascia Anatomy-Oriented Differential Nodal CTV Delineation at the Supraclavicular Region for Esophageal Cancer and Nasopharyngeal Cancer.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04531.
    PubMed    


  8. CHOW JCH, Lui JCF, Cheung KM, Tam AHP, et al
    Post-radiation primary hypothyroidism in patients with head and neck cancer: External validation of thyroid gland dose-volume constraints with long-term endocrine outcomes.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04529.
    PubMed     Abstract available


  9. HUANG H, Miao J, Zhao C, Wang L, et al
    Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing inten
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04517.
    PubMed    


  10. SARODE GS, Sarode SC, Anand R
    Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective pha
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04515.
    PubMed    


  11. LEE CT, Litwin S, Yao CMKL, Liu JC, et al
    Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints.
    Radiother Oncol. 2022;176:215-221.
    PubMed     Abstract available


  12. VAN DER WEIJST L, Azria D, Berkovic P, Boisselier P, et al
    The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
    Radiother Oncol. 2022;176:127-137.
    PubMed     Abstract available


    October 2022
  13. ROESCH J, Oertel M, Wegen S, Trommer M, et al
    Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
    Radiother Oncol. 2022 Oct 20. pii: S0167-8140(22)04502.
    PubMed     Abstract available


  14. TIEN CT, Chen CN, Young YH
    Post-irradiation endolymphatic hydrops vs. post-irradiation sudden deafness.
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04504.
    PubMed     Abstract available


  15. RONN HANSEN C, Price G, Field M, Sarup N, et al
    Larynx cancer survival model developed through open-source federated learning.
    Radiother Oncol. 2022 Oct 5. pii: S0167-8140(22)04493.
    PubMed     Abstract available


    September 2022
  16. NADERI E, Schack LMH, Welsh C, Sim AYL, et al
    Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer.
    Radiother Oncol. 2022 Sep 30. pii: S0167-8140(22)04486.
    PubMed     Abstract available


  17. HUMBERT-VIDAN L, Hansen CR, Fuller CD, Petit S, et al
    Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for Mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN).
    Radiother Oncol. 2022 Sep 27. pii: S0167-8140(22)04473.
    PubMed    


  18. DRAGUET C, Barragan-Montero AM, Chocan Vera M, Thomas M, et al
    Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancer.
    Radiother Oncol. 2022 Sep 24. pii: S0167-8140(22)04263.
    PubMed     Abstract available


  19. OUD M, Breedveld S, Gizynska M, Kroesen M, et al
    An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer.
    Radiother Oncol. 2022 Sep 20. pii: S0167-8140(22)04278.
    PubMed     Abstract available


    August 2022
  20. DE ROEST RH, van der Heijden M, W R Wesseling F, de Ruiter EJ, et al
    Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    Radiother Oncol. 2022 Aug 13. pii: S0167-8140(22)04234.
    PubMed     Abstract available


  21. ZHANG Y, Alshaikhi J, Amos RA, Lowe M, et al
    Improving workflow for adaptive proton therapy with predictive anatomical modelling: A proof of concept.
    Radiother Oncol. 2022;173:93-101.
    PubMed     Abstract available


    July 2022
  22. GHATASHEH H, Hui Huang S, Su J, Xu W, et al
    Evaluation of risk-tailored individualized selection of radiation therapy target volume for Head and Neck Carcinoma of Unknown Primary.
    Radiother Oncol. 2022 Jul 26. pii: S0167-8140(22)04214.
    PubMed     Abstract available


  23. HABRICH J, Boeke S, Nachbar M, Nikolaou K, et al
    Repeatability of diffusion-weighted magnetic resonance imaging in head and neck cancer at a 1.5 T MR-Linac.
    Radiother Oncol. 2022 Jul 25. pii: S0167-8140(22)04218.
    PubMed     Abstract available


  24. HUANG H, Miao J, Xiao X, Hu J, et al
    Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): a prospective phase II randomized controlled study.
    Radiother Oncol. 2022 Jul 8. pii: S0167-8140(22)04191.
    PubMed     Abstract available


  25. PRICE JM, West CM, Dixon LM, Iyizoba-Ebozue Z, et al
    Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharyngeal cancer: A multi-centre study.
    Radiother Oncol. 2022;172:111-117.
    PubMed     Abstract available


    June 2022
  26. QIAN D, Chen X, Shang X, Wang Y, et al
    Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II rando
    Radiother Oncol. 2022 Jun 25. pii: S0167-8140(22)04176.
    PubMed     Abstract available


  27. KROESE TE, Christ SM, van Rossum PSN, Burger MDL, et al
    Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study.
    Radiother Oncol. 2022 Jun 23. pii: S0167-8140(22)04173.
    PubMed     Abstract available


  28. GONG J, Zhang W, Huang W, Liao Y, et al
    CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: a multicenter study.
    Radiother Oncol. 2022 Jun 21. pii: S0167-8140(22)04171.
    PubMed     Abstract available


  29. HANSEN CR, Price G, Field M, Sarup N, et al
    Open-source distributed learning validation for a larynx cancer survival model following radiotherapy.
    Radiother Oncol. 2022 Jun 20. pii: S0167-8140(22)04170.
    PubMed     Abstract available


  30. FU G, Xie Y, Pan J, Qiu Y, et al
    Longitudinal study of irradiation-induced brain functional network alterations in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Jun 16. pii: S0167-8140(22)04164.
    PubMed     Abstract available


  31. SCHOONBEEK RC, Festen S, van der Laan BFAM, Plaat BEC, et al
    The effect of delayed treatment initiation on adverse events and recurrence in older head and neck cancer patients.
    Radiother Oncol. 2022 Jun 6. pii: S0167-8140(22)04146.
    PubMed     Abstract available


  32. MASSACCESI M, Dinapoli N, Fuga V, Rupe C, et al
    A predictive nomogram for trismus after radiotherapy for head and neck cancer.
    Radiother Oncol. 2022 Jun 2. pii: S0167-8140(22)04137.
    PubMed     Abstract available


    May 2022
  33. LIU Z, Luo Y, Guo R, Yang B, et al
    Head and Neck Radiotherapy Causes Significant Disruptions of Cochlear Ribbon Synapses and Consequent Sensorineural Hearing Loss.
    Radiother Oncol. 2022 May 28. pii: S0167-8140(22)02279.
    PubMed     Abstract available


  34. ZHAO DW, Fan WJ, Fang XM, Luo YR, et al
    Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
    Radiother Oncol. 2022 May 15. pii: S0167-8140(22)00251.
    PubMed     Abstract available


  35. YI-LIANG SHEN E, Hung TM, Tsan DL, Cheng NM, et al
    Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating epstein-barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 May 11. pii: S0167-8140(22)00240.
    PubMed     Abstract available


    April 2022
  36. ZHAO Y, Liao X, Wang Y, Lan W, et al
    Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy.
    Radiother Oncol. 2022 Apr 29. pii: S0167-8140(22)00232.
    PubMed     Abstract available


  37. DOHOPOLSKI M, Wang K, Morgan H, Sher D, et al
    Predicting the need for aggressive nutritional supplementation in head and neck cancer patients receiving radiation therapy.
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00224.
    PubMed     Abstract available


  38. SHEN H, Yin J, Niu R, Lian Y, et al
    Development and validation of a radiomic nomogram to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carc
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00222.
    PubMed     Abstract available


  39. LEE BM, Lee CG
    Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer.
    Radiother Oncol. 2022 Apr 18. pii: S0167-8140(22)00191.
    PubMed     Abstract available


  40. WELZ S, Paulsen F, Pfannenberg C, Reimold M, et al
    Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [(18)F]FMISO PET/CT.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00170.
    PubMed     Abstract available


  41. JENSEN KH, Vogelius IR, Bernsdorf M, Gothelf A, et al
    Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00169.
    PubMed     Abstract available


  42. LUDWIG R, Hoffmann JM, Pouymayou B, Dappen MB, et al
    Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface.
    Radiother Oncol. 2022;169:1-7.
    PubMed     Abstract available


    March 2022
  43. YUE M, Xue X, Wang Z, Lambo RL, et al
    Dose prediction via distance-guided deep learning: initial development for nasopharyngeal carcinoma radiotherapy.
    Radiother Oncol. 2022 Mar 26. pii: S0167-8140(22)00150.
    PubMed     Abstract available


  44. BORDERIAS-VILLARROEL E, Taasti V, Van Elmpt W, Teruel-Rivas S, et al
    Evaluation of the clinical value of automatic online dose restoration for adaptive proton therapy of head and neck cancer.
    Radiother Oncol. 2022 Mar 25. pii: S0167-8140(22)00149.
    PubMed     Abstract available


  45. KARAVOLIA E, van Rijn-Dekker MI, Van den Bosch L, van den Hoek JGM, et al
    Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients.
    Radiother Oncol. 2022 Mar 15. pii: S0167-8140(22)00145.
    PubMed     Abstract available


  46. ZHOU X, Wang W, Zhou C, Zhu J, et al
    Long-term outcomes of replanning during intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: An updated and expanded retrospective analysis.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00132.
    PubMed     Abstract available


  47. HUANG CC, Lai YR, Chiu WC, Fang FM, et al
    Concurrent chemoradiation therapy is associated with an accelerated risk of cardiovascular autonomic dysfunction in patients with nasopharyngeal carcinoma: A 9-year prospective follow-up study.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00129.
    PubMed     Abstract available


  48. CHOW R, Simone CB 2nd
    Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality.
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00112.
    PubMed    


  49. DAI D, Tian Q, Shui Y, Li J, et al
    Response to "Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality".
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00109.
    PubMed    


  50. NACHANKAR A, Musha A, Kubo N, Kawamura H, et al
    Dosimetric analysis of intraocular hemorrhage in nonsquamous head and neck cancers treated with carbon-ion radiotherapy.
    Radiother Oncol. 2022 Mar 4. pii: S0167-8140(22)00118.
    PubMed     Abstract available


  51. GORPHE P, Classe M, Ammari S, Garcia G, et al
    Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma.
    Radiother Oncol. 2022;168:40-45.
    PubMed     Abstract available


    February 2022
  52. LASKAR SG, Sinha S, Pai DP, Nair D, et al
    Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes.
    Radiother Oncol. 2022 Feb 24. pii: S0167-8140(22)00106.
    PubMed     Abstract available


  53. BONOMO P, Desideri I, Mangoni M, Saieva C, et al
    Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial.
    Radiother Oncol. 2022 Feb 11. pii: S0167-8140(22)00091.
    PubMed     Abstract available


  54. SCANDURRA D, Meijer TWH, Free J, van den Hoek JGM, et al
    Evaluation of robustly optimised intensity modulated proton therapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Feb 5. pii: S0167-8140(22)00080.
    PubMed     Abstract available


  55. PAN D, Rong X, Zhu Y, Ng WT, et al
    A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis.
    Radiother Oncol. 2022 Feb 1. pii: S0167-8140(22)00060.
    PubMed     Abstract available


    January 2022
  56. SUN XS, Zhu MY, Wen DX, Luo DH, et al
    Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in local recurrence nasopharyngeal carcinoma patients.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00028.
    PubMed     Abstract available


  57. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Head and neck cancer diagnoses and faster treatment initiation during COVID-19: correspondence.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00026.
    PubMed    


  58. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Response to "Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence".
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00033.
    PubMed    


  59. CHATTERJEE S, Maulik S, Prasath S, Arun B, et al
    Xerostomia quality of life and resource requirements following parotid sparing adaptive radiotherapy in head and neck cancers: Results of a prospective cohort study (Study ID CTRI/2017/11/010683).
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00024.
    PubMed     Abstract available


  60. ZECH HB, Berger J, Mansour WY, Nordquist L, et al
    Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00022.
    PubMed     Abstract available


  61. AL-MAMGANI A, Kessels R, Janssen T, Navran A, et al
    The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: significant acute and late toxicity reduction.
    Radiother Oncol. 2022 Jan 20. pii: S0167-8140(22)00017.
    PubMed     Abstract available


  62. HE J, Qian L, Gao J
    Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00005.
    PubMed    


  63. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)"by He et al.
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00006.
    PubMed    


  64. DAI D, Tian Q, Shui Y, Li J, et al
    The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis.
    Radiother Oncol. 2022 Jan 8. pii: S0167-8140(22)00007.
    PubMed     Abstract available


  65. HUANG W, Zhang Q, Wu G, Chen P, et al
    Corrigendum to "DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients" [Radiother Oncol (2021) 164:146-154].
    Radiother Oncol. 2022 Jan 7. pii: S0167-8140(21)09059.
    PubMed    


  66. LIU T, Shen BW, Liu LT, Yang ZC, et al
    Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model.
    Radiother Oncol. 2022 Jan 5. pii: S0167-8140(21)09094.
    PubMed     Abstract available


  67. FORNER LE, Dieleman FJ, Shaw RJ, Kanatas A, et al
    Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1.
    Radiother Oncol. 2022;166:137-144.
    PubMed     Abstract available


    December 2021
  68. GUO Q, Xiao N, Xu H, Zong J, et al
    Rationality of the international guideline's recommendation regarding selective coverage of level Ib in clinical target volume with nasopharyngeal carcinoma: Results from a real-world series.
    Radiother Oncol. 2021 Dec 29. pii: S0167-8140(21)09081.
    PubMed     Abstract available


  69. TANG SQ, Chen L, Li WF, Chan ATC, et al
    Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9,468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
    Radiother Oncol. 2021 Dec 28. pii: S0167-8140(21)09077.
    PubMed     Abstract available


  70. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: a nationwide population-based analysis.
    Radiother Oncol. 2021 Dec 13. pii: S0167-8140(21)09049.
    PubMed     Abstract available


  71. MUSHA A, Hirai C, Kitada Y, Tsunoda A, et al
    Relationship between oral mucositis and the oral bacterial count in patients with head and neck cancer undergoing carbon ion radiotherapy: A prospective study.
    Radiother Oncol. 2021 Dec 10. pii: S0167-8140(21)09054.
    PubMed     Abstract available


  72. BEUKEMA JC, de Groot C, Plukker JTM, Vliegenthart R, et al
    Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study.
    Radiother Oncol. 2021 Dec 2. pii: S0167-8140(21)09025.
    PubMed     Abstract available


    November 2021
  73. KUTZ LM, Abel J, Schweizer D, Tribius S, et al
    Quality of life, HPV-status and phase angle predict survival in head and neck cancer patients under (chemo)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09004.
    PubMed     Abstract available


  74. JIN YN, Yang QQ, Li ZQ, Ou XQ, et al
    Development of a Web-based Prognostic Model to Quantify the Survival Benefit of Cumulative Cisplatin Dose during Concurrent Chemoradiotherapy in Childhood Nasopharyngeal Carcinoma.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09008.
    PubMed     Abstract available


  75. NISHIBUCHI I, Murakami Y, Kubo K, Imano N, et al
    Temporal Changes and Risk Factors for Esophageal Stenosis after Salvage Radiotherapy in Superficial Esophageal Cancer following Non-Curative Endoscopic Submucosal Dissection.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09007.
    PubMed     Abstract available


  76. PATEL V, Kwok J, Burke M, Urbano TG, et al
    Should the HPV positive oropharyngeal cancer patient be considered for a two-stage dental assessment for their radiation treatment?
    Radiother Oncol. 2021;164:232-235.
    PubMed     Abstract available


  77. GAWRYSZUK A, Bijl HP, van der Schaaf A, Perdok N, et al
    Relationship between videofluoroscopic and subjective (physician- and patient- rated) assessment of late swallowing dysfunction after (chemo) radiation: Results of a prospective observational study.
    Radiother Oncol. 2021;164:253-260.
    PubMed     Abstract available


    October 2021
  78. BROOKER RC, Antczak P, Liloglou T, Risk JM, et al
    Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy.
    Radiother Oncol. 2021;165:87-93.
    PubMed     Abstract available


  79. CHIN O, Yu E, O'Sullivan B, Su J, et al
    Prognostic Importance of Radiologic Extranodal Extension in Nasopharyngeal Carcinoma Treated in a Canadian Cohort.
    Radiother Oncol. 2021 Oct 27. pii: S0167-8140(21)08785.
    PubMed     Abstract available


  80. ZHANG ZM, Zhao R, Bao Y, Zhou LX, et al
    A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08758.
    PubMed     Abstract available


  81. SHI Z, Zhu X, Ke S, Qiu H, et al
    Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08754.
    PubMed     Abstract available


  82. YAN A, Hanna A, Wilson TG, Deraniyagala R, et al
    Correlation between tumor voxel dose response matrix and tumor biomarker profile in patients with head and neck squamous cell carcinoma.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)08748.
    PubMed     Abstract available


  83. KANEHIRA T, van Kranen S, Jansen T, Hamming-Vrieze O, et al
    Comparisons of normal tissue complication probability models derived from planned and delivered dose for head and neck cancer patients.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)06738.
    PubMed     Abstract available


    September 2021
  84. HUANG W, Zhang Q, Wu G, Pian Chen P, et al
    DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients.
    Radiother Oncol. 2021 Sep 27. pii: S0167-8140(21)06739.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: